23:25 , Nov 15, 2017 |  BC Extra  |  Company News

Management tracks: Outpost, Torque

Genitourinary play Outpost Medicine LLC (Indianapolis, Ind.) named Scott Byrd president and CEO. He succeeds interim CEO David Socks, who will remain on the company's board. Byrd was president and COO at the Acacia Pharma...
23:48 , Aug 22, 2017 |  BC Extra  |  Company News

Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and...
16:54 , May 12, 2017 |  BioCentury  |  Product Development

Stepwise to a cure

Phase IIa data for ABX464 from Abivax S.A.S. are a step in the right direction toward a functional cure, but the company will need to show the therapy can achieve much greater reductions in HIV...
23:05 , Feb 2, 2017 |  BC Innovations  |  Strategy

Cure cash

With the goal now to clear rather than just suppress HIV, Gilead Sciences Inc. is using a $22 million grant program to back the scientific strategies it thinks are most likely to empty the HIV...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

Vacc-4x: Additional Phase I/II data

Data from 17 evaluable patients with HIV-1 infection in Part B of the open-label, Danish Phase I/II REDUC trial showed that Vacc-4x plus GM-CSF adjuvant followed by 5 mg/m 2 IV Istodax romidepsin -- a...
01:49 , Dec 22, 2015 |  BC Extra  |  Clinical News

Bionor reports latent HIV reservoir reductions

Bionor Pharma ASA (OSE:BIONOR) said its Vacc-4x in combination with cancer drug Istodax romidepsin significantly reduced latent HIV reservoirs among patients in Part B of the Danish Phase I/II REDUC trial. Viral load remained below...
01:50 , Mar 28, 2015 |  BC Extra  |  Company News

Management tracks

Bionor Pharma ASA (OSE:BIONOR) announced a trio of hires. Soren Keller is joining as SVP, COO and interim CFO. Keller was director and general counsel to the management at Zealand Pharma A/S (CSE:ZEAL). Kamilla Rolsted...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Company News

Bionor Pharma management update

Bionor Pharma ASA (OSE:BIONOR), Oslo, Norway   Business: Infectious, Nutraceuticals   Hired: David Solomon as president and CEO, formerly president and CEO of Zealand Pharma A/S ; he succeeds CEO Anker Lundemose  ...
08:00 , Jan 19, 2015 |  BC Week In Review  |  Company News

Mission Therapeutics management update

Mission Therapeutics Ltd. , Cambridge, U.K.   Business: Cancer   Hired: Anker Lundemose as CEO, formerly CEO of Bionor Pharma ASA  ...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

Vacc-4x: Phase I/II data

Data from 6 patients with HIV-1 infection on cART with undetectable HIV-1 RNA levels in Part A of the open-label, Danish Phase I/II REDUC trial showed that 5 mg/m 2 IV Istodax romidepsin - a...